+357 96 030922
info@marketpublishers.com

U.S. Attention Deficit Hyperactivity Disorder Market Size, Share, & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, And Segment Forecasts, 2025 - 2033

https://marketpublishers.com/r/U1084EBD21FEEN.html
Date: July 2025
Pages: 80
Price: US$ 5,950.00 (Single User License)
ID: U1084EBD21FEEN

Abstracts

This report can be delivered to the clients within 2 Business Days

U.S. Attention Deficit Hyperactivity Disorder Market Summary

The U.S. attention deficit hyperactivity disorder market size was estimated at USD 10.31 billion in 2024 and is projected to reach USD 13.88 billion by 2033, growing at a CAGR of 3.3% from 2025 to 2033. The market is primarily driven by a continuous increase in diagnosed cases, supported by expanded diagnostic criteria, greater public awareness, and more consistent screening in primary care settings.

Attention Deficit Hyperactivity Disorder (ADHD) remains one of the most commonly diagnosed neurodevelopmental disorders in the U.S., shaping clinical practice and public health initiatives. A 2020-2022 National Health Interview Survey reported that 11.3% of U.S. children aged 5 to 17 have been diagnosed with ADHD at some point. Boys (14.5%) are nearly twice as likely as girls (8.0%) to receive a diagnosis. Similar trends are seen in adults, with lifetime ADHD prevalence estimated at around 8.1% among those aged 18 to 44.

Growing awareness among caregivers and educators, driven by school screening programs and destigmatization efforts, is further expanding the pool of patients being identified. Innovation in treatment options is another major driver of growth of the U.S. attention deficit hyperactivity disorder industry. Although stimulant medications such as

methylphenidate and amphetamines continue to dominate prescriptions, recent advances highlight the market's shift toward non-stimulant and digital therapies. In December 2023, the FDA expanded the indication for EndeavorRx, the first game-based digital therapeutic, to include adolescents aged 13 to 17, following pivotal STARS-ADHD trial data showing significant attention improvements on TOVA assessments (p Changes in care delivery and payer policies continue to influence market dynamics. The widespread adoption of telehealth, accelerated by the COVID-19 pandemic, has reduced barriers to ongoing treatment by facilitating more frequent follow-ups and dose adjustments. In addition, updated insurance coverage guidelines now commonly reimburse digital and behavioral therapies alongside medication. Integrated care models that combine behavioral therapy with medication management within pediatric and adolescent health networks are becoming increasingly prominent, especially as comorbid conditions such as anxiety and learning disorders receive greater attention. In January 2025, Supernus Pharmaceuticals obtained an FDA label update for Qelbree, adding new pharmacodynamic data and information on breastfeeding women.

M&A activity in the ADHD segment is relatively selective, primarily involving specialty pharmaceutical companies aiming to broaden their therapeutic or digital health portfolios. In September 2024, Collegium Pharmaceutical acquired Ironshore Therapeutics. The deal expanded Collegium's reach in the neurology sector, specifically in the ADHD market, and added Jornay PM, a stimulant to treat ADHD, to its portfolio.

U.S. Attention Deficit Hyperactivity Disorder Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. attention deficit hyperactivity disorder market report based on drug type, demographics, and distribution channel:

Drug Type Outlook (Revenue, USD Million, 2021 - 2033)

Stimulants

Amphetamine

Methylphenidate

Lisdexamfetamine

+357 96 030922
info@marketpublishers.com

Dexmethylphenidate

Non-stimulants

Atomoxetine

Guanfacine

Clonidine

Others

Demographics Outlook (Revenue, USD Million, 2021 - 2033)

Children

Adults

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

Retail Pharmacy

Hospital Pharmacy

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 4. U.S. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: U.S. Attention Deficit Hyperactivity Disorder Market Size, Share, & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, And Segment Forecasts, 2025 - 2033

Product link: https://marketpublishers.com/r/U1084EBD21FEEN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U1084EBD21FEEN.html